Skip to main content
. 2020 Apr 22;12(4):1163. doi: 10.3390/nu12041163

Table 4.

Results of RCTs.

Author, Year Outcomes Evaluated Mean (SD) Baseline 25OHD (nmol/L) Mean (SD) Endline 25OHD (nmol/L) Mean (SD) Baseline BP (mmHg) Mean (SD) Endline BP (mmHg) Conclusion
Al Daghri, 2019 [28] 25OHD: enzyme linked immunosorbent assay Tablet: 30.8 (9.3)
Milk: 31.8 (8.1)
C: 29.8 (10.3) (p = 0.46)
Tablet: 41.5 (14.4)
Milk: 38.1 (11.9)
C: 31.9 (13.8) (p < 0.001)
(p = 0.73 between tablet and milk; <0.001 between tablet and C; p < 0.001 between milk and control)
SBP:
Tablet: 117.3 (14.4)
Milk: 117.9 (14.4)
C: 120.9 (14.9) (p = 0.75)
SBP:
Tablet: 112.3 (12.3)
Milk: 115.3 (16.1)
C: 117.1 (14.9) (p = 0.005) (p = 0.44 between tablet and milk; p = 0.004 between tablet and C; p = 0.19 between milk and C)
Significant decrease in SBP in all groups. Between-group significant decrease in favor of the tablet group (p = 0.005)
SBP and DBP: average of 2 measures by a conventional mercurial sphygmomanometer taken after a 30-minute rest DBP:
Tablet: 71.9 (11.9)
Milk: 73.3 (15.7)
C: 72.5 (11.6) (p = 0.50)
DBP:
Tablet: 69 (11.4)
Milk: 75.6 (15.7)
C: 68.1 (11.1) (p < 0.001)
(p < 0.001 between tablet and milk; p = 0.94 between tablet and C; p < 0.001 between milk and C)
Significant decrease in DBP in the tablet and control groups. Between-group significant improvement in favor of control (p < 0.001)
Elevated BP: ≥90th percentile for age, sex and height Elevated BP:
Tablet: 38.9%
Milk: 40.7%
C: 34.9%
Elevated BP:
Tablet: 25.0% (p < 0.001)
Milk: 44.4% (NS)
C: 24.7% (p < 0.05)
Significant reduction in elevated BP in the tablet and control groups (p < 0.05)
Dong, 2010 [29] Plasma 25OHD: enzyme immunoassay I: 33.1 (8.7)
C: 34.0 (10.6) (p = 0.76)
I: 85.7 (30.1)
C: 59.8 (18.2) (p < 0.001)
SBPI: 111.3 (10.4)
C: 114.9 (7.8) (p = 0.20)
NR NS change in SBP or DBP over time in the control or intervention groups (p > 0.05)
SBP and DBP: average of 3 measures, 2 minutes apart, by a vital signs monitor after a 5-minute rest DBP
I:68.2 (12.3)
C: 69.4 (6.5) (p = 0.17)
Hauger, 2018 [32] Serum 25OHD: liquid chromatography-tandem
mass spectrometry
I1: 56.9 (12.7)
I2: 58.1 (13.5)
C: 55.2 (10.8)
I1: 61.8 (10.6)
I2: 75.8 (11.5)
C: 31.1 (7.5) (p < 0.001)
SBP:
I1: 95.7 (4.6)
I2: 96.4 (4.4)
C: 97.1 (5.5)
SBP:
I1: 95.6 (4.4)
I2: 96.9 (4.4)
C: 96.6 (4.2) (NS)
NS change in SBP or DBP when adjusted for baseline value of the outcome
Marginally higher DBP of 1.4 mmHg (95% CI: −0.0,2.8; p = 0.05) in I1 compared with I2
SBP and DBP: average of 2 out of 3 readings, 10 minutes apart, by an automated monitor in a supine position DBP:
I1: 58.8 (4.1)
I2: 59.9 (4.6)
C: 59.2 (4.1)
DBP:
I1: 58.5 (4.5)
I2: 60.5 (3.8)
C: 59.9 (3.3) (NS)
Marginally lower DBP of −1.2mmHg (95% CI: −2.7, −0.0; p = 0.05) in I1 compared with C, which was not observed with I2
Kelishadi, 2014 [30] Serum 25OHD: chemiluminescent immunoassay method I: 45.60 (5.09)
C: 44.7 (5.66) (p = 0.48)
I: 79.89 (5.34)
C: 47.59 (5.01) (p = 0.02)
I: 134.01 (5.89)
C: 136.61 (6.08) (p = 0.53)
I: 131.47 (4.69)
C: 135.26 (4.52) (p = 0.07)
NS change in mean arterial pressure in intra-group and inter-group comparisons
Mean arterial pressure: ((SBP − DBP)/3) + DBP; with SBP and DBP measured using standard protocol with calibrated instruments (procedure not detailed)
Smith, 2018 [31] Serum 25OHD: liquid chromatography-tandem mass spectrometry I1: 49.2 (12)
I2: 51.7 (13.4)
C: 46.9 (11.4)
I1: 56.6 (12.4)
I2: 63.9 (10.6)
C: 30.7 (8.6) (p < 0.001 for all groups, from baseline to endline)
SBP:
I1: 124 (13)
I2:122 (10)
C: 121 (10)
SBP:
I1: 123 (11)
I2: 121 (8)
C: 123 (14) (NS)
NS change in SBP or DBP
SBP and DBP: average of 3 readings, 1 min apart, by an automated BP monitor on the non-dominant arm in an upright position with the arm supported DBP:
I1: 69 (10)
I2: 67 (7)
C: 67 (8)
DBP:
I1: 71 (11)
I2: 67 (6)
C: 68 (10) (NS)

SD: standard deviation; 25OHD: 25-hydroxyvitamin D; BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; C: control; I: intervention; NR: not reported; NS: not significant.